Literature DB >> 28910167

Expression of Antimicrobial Peptides by Uveal and Cutaneous Melanoma Cells and Investigation of Their Role in Tumor Cell Migration and Vasculogenic Mimicry.

Joseph C Manarang1, Deborah C Otteson1, Alison M McDermott1.   

Abstract

AIMS: Antimicrobial peptides (AMPs) have been implicated in the pathogenesis of several cancers, although there is also evidence suggesting potential for novel, AMP-based antitumor therapies. Discerning potential roles of AMPs in tumor pathogenesis may provide valuable insight into the mechanisms of novel AMP-based antitumor therapy.
METHODS: mRNA expression of the AMPs α defensin (HNP-1); cathelicidin (LL-37); and β defensins (hBD-1, hBD-2, hBD-3, hBD-4) in human uveal and cutaneous melanoma cell lines, primary human uveal melanocytes, and primary human uveal melanoma cells was determined by reverse transcriptase polymerase chain reaction. An in vitro scratch assay and custom Matlab analysis were used to determine the AMP effects on melanoma cell migration. Last, the effect of specific AMPs on vasculogenic mimicry was determined by three-dimensional (3D) culture and light and fluorescence microscopy.
RESULTS: Low-to-moderate AMP transcript levels were detected, and these varied across the cells tested. Overall, LL-37 expression was increased while hBD-4 was decreased in most melanoma cell lines, compared to primary cultured uveal melanocytes. There was no observable influence of HNP-1 and LL-37 on tumor cell migration. Additionally, aggressive cutaneous melanoma cells grown in 3D cultures exhibited vasculogenic mimicry, although AMP exposure did not alter this process.
CONCLUSIONS: Collectively, our data show that although AMP mRNA expression is variable between uveal and cutaneous melanoma cells, these peptides have little influence on major characteristics that contribute to tumor aggressiveness and progression.

Entities:  

Keywords:  antimicrobial peptide; cutaneous melanoma; uveal melanoma; vasculogenic mimicry

Mesh:

Substances:

Year:  2017        PMID: 28910167      PMCID: PMC6141659          DOI: 10.1080/02713683.2017.1339806

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  46 in total

1.  The antimicrobial peptide human cationic antimicrobial protein-18/cathelicidin LL-37 as a putative growth factor for malignant melanoma.

Authors:  J E Kim; H J Kim; J M Choi; K H Lee; T Y Kim; B K Cho; J Y Jung; K Y Chung; D Cho; H J Park
Journal:  Br J Dermatol       Date:  2010-11       Impact factor: 9.302

Review 2.  Uveal Melanoma Cell Lines: Where do they come from? (An American Ophthalmological Society Thesis).

Authors:  Martine J Jager; J Antonio Bermudez Magner; Bruce R Ksander; Sander R Dubovy
Journal:  Trans Am Ophthalmol Soc       Date:  2016-08

Review 3.  Ocular melanoma: an overview of the current status.

Authors:  Predrag Jovanovic; Marija Mihajlovic; Jasmina Djordjevic-Jocic; Slobodan Vlajkovic; Sonja Cekic; Vladisav Stefanovic
Journal:  Int J Clin Exp Pathol       Date:  2013-06-15

4.  Human alpha-defensins HNPs-1, -2, and -3 in renal cell carcinoma: influences on tumor cell proliferation.

Authors:  Claudia A Müller; Jasmina Markovic-Lipkovski; Tatjana Klatt; Jutta Gamper; Gerold Schwarz; Hermann Beck; Martin Deeg; Hubert Kalbacher; Susanne Widmann; Johannes T Wessels; Volker Becker; Gerhard A Müller; Thomas Flad
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

5.  Expression of human beta-defensins in conjunctival epithelium: relevance to dry eye disease.

Authors:  Srihari Narayanan; William L Miller; Alison M McDermott
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-09       Impact factor: 4.799

6.  An angiogenic role for the human peptide antibiotic LL-37/hCAP-18.

Authors:  Rembert Koczulla; Georges von Degenfeld; Christian Kupatt; Florian Krötz; Stefan Zahler; Torsten Gloe; Katja Issbrücker; Pia Unterberger; Mohamed Zaiou; Corinna Lebherz; Alexander Karl; Philip Raake; Achim Pfosser; Peter Boekstegers; Ulrich Welsch; Pieter S Hiemstra; Claus Vogelmeier; Richard L Gallo; Matthias Clauss; Robert Bals
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

7.  Identification of multiple novel epididymis-specific beta-defensin isoforms in humans and mice.

Authors:  Yasuhiro Yamaguchi; Takahide Nagase; Ryosuke Makita; Shigetomo Fukuhara; Tetsuji Tomita; Takashi Tominaga; Hiroki Kurihara; Yasuyoshi Ouchi
Journal:  J Immunol       Date:  2002-09-01       Impact factor: 5.422

Review 8.  The Human Cathelicidin Antimicrobial Peptide LL-37 and Mimics are Potential Anticancer Drugs.

Authors:  Kengo Kuroda; Kazuhiko Okumura; Hiroshi Isogai; Emiko Isogai
Journal:  Front Oncol       Date:  2015-06-30       Impact factor: 6.244

9.  Expression and new exon mutations of the human Beta defensins and their association on colon cancer development.

Authors:  Abdelhabib Semlali; Abdullah Al Amri; Arezki Azzi; Omair Al Shahrani; Maha Arafah; Muhammad Kohailan; Abdulrahman M Aljebreen; Othman Alharbi; Majid A Almadi; Nahla Ali Azzam; Narasimha Reddy Parine; Mahmoud Rouabhia; Mohammad S Alanazi
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

10.  Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice.

Authors:  Y C Yoo; S Watanabe; R Watanabe; K Hata; K Shimazaki; I Azuma
Journal:  Jpn J Cancer Res       Date:  1997-02
View more
  2 in total

1.  Evaluation of Pharmaceutical Inhibition of Vasculogenic Mimicry In Vitro.

Authors:  Joseph C Manarang; Alison McDermott
Journal:  Methods Mol Biol       Date:  2022

2.  Evaluation of 99m Tc-MccJ25 peptide analog in mice bearing B16F10 melanoma tumor as a diagnostic radiotracer.

Authors:  Maryam Mazaheri Tehrani; Mostafa Erfani; Nour Amirmozafari; Taher Nejadsattari
Journal:  Asia Ocean J Nucl Med Biol       Date:  2019
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.